drugset / Trial / NCT05407324
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this 2-part study is to assess the safety and efficacy of CORT113176 (dazucorilant) in patients with Amyotrophic Lateral Sclerosis (ALS).
Timeline
- Start
- 2022-11-15
- Primary completion
- 2026-10
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dazucorilant | Small molecule | 150 mg | — |
| Subject | Dazucorilant | Small molecule | 300 mg | — |